



Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

Hong DS, et al. Lancet Oncol 2020; 21:531-40



Larotrectinib Selective TRK inhibitor




159 patients

Adults + children with TRK fusion-positive cancer



0.03 to 47.2 months

Durations of treatment



mDoR
35.2 months

mPFS
28.3 months

mOS
44.4 months

ORR
79%

TRK, tropomyosin receptor kinase; NTRK, neurotrophic tyrosine receptor kinase; GIST, gastrointestinal stromal tumour; IFS, infantile fibrosarcoma; mDoR, median duration of response; mPFS; median progression-free survival; mOS, median overall survival; ORR, objective response rate.

This content is supported by an Independent Educational Grant from Bayer